Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

29,822 signal articles · 40 in last 24h · 148,715 total before filter · latest 1h ago
40last 24h
979last 7d
107● bullish (7d)
123● bearish (7d)
212publishers
AllMacro373Earnings111M&A97Regulatory9Product13Analyst7
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearishshow all (incl. clickbait)
European Indexes Mixed, Autos Rally
The Wall Street Journal31d agobullish
European Indexes Mixed, Autos Rally

European stock indexes were mixed, with gains in autos and semiconductors unable to lift the lift the Europe-wide Stoxx 600 index.

Asian shares gain, with South Korea's Kospi up 6%, after the US Treasury expands its debt buybacks
Associated Press31d agobullish
Asian shares gain, with South Korea's Kospi up 6%, after the US Treasury expands its debt buybacks

U.S. futures edged higher after the U.S. Treasury Department said it would at least double the size of planned purchases of longer-term government debt. Japan’s Nikkei 225 gained 1.3% to 66,178.26, reversing declines earlier in the week. Japan reported it logged a trade deficit for a third straight month in July, as both imports and exports hit record highs.

Analysis-Moderna, Merck breakthrough could usher in wave of cancer vaccines
Reuters31d agobullish
Analysis-Moderna, Merck breakthrough could usher in wave of cancer vaccines

CHICAGO, Aug 19 () - Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors. Unlike chemotherapy, which kills both healthy and cancerous cells, or immunotherapy, which revs up the immune system, personalized cancer ‌vaccines train the immune system to specifically target mutations found only on a person's tumor.

Moderna Stock Soars on Cancer Vaccine Success
The Wall Street Journal31d agobullish
Moderna Stock Soars on Cancer Vaccine Success

1. Moderna shares more than doubled after it reported successful results in an experimental mRNA-based cancer vaccine. The company and its partner Merck reported this morning that the vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients. The positive results sent Moderna’s share price soaring and rippled through drug industry stocks as investors saw the potential for more future blockbusters.